Efficacy of YL-1 hematoma crushing needle combined with hematoma drainage in intracerebral hemorrhage treatment

TL;DR

A new surgical tool called the YL-1 needle may improve recovery for patients with brain hemorrhages by speeding up clot removal and improving patient outcomes.

Contribution

This study evaluates the clinical efficacy of the YL-1 hematoma crushing needle combined with drainage in treating intracerebral hemorrhage.

Findings

Surgical group had significantly shorter hematoma resolution time compared to the conservative group.

The surgical group showed greater improvement in Barthel Index and Glasgow Coma Scale scores.

Mannitol administration duration was significantly reduced in the surgical group.

Abstract

Early craniotomy evacuation in hematoma surgery does not significantly improve the prognosis of patients with spontaneous intracerebral hemorrhage (ICH). The YL-1 hematoma crushing puncture needle, specifically designed for ICH evacuation, has an uncertain therapeutic efficacy. This study aimed to evaluate its clinical effectiveness.

We retrospectively reviewed medical records of patients with ICH who underwent twist intraosseous drill needle (TIDN) surgery at our institution between September 2016 and March 2023. Clinical outcomes were analyzed.

The surgical group demonstrated a significantly shorter hematoma resolution time, averaging 14.71 days less than the conservative group (p < 0.001). The Barthel Index improved more in the surgical group, with an average increase of 8.214 points (p < 0.001). Seven days post-admission, the increase in Glasgow Coma Scale (GCS) scores was significantly higher in the surgical group, with an average improvement of 1.471 points (p < 0.001). Additionally, the duration of mannitol administration was significantly reduced in the surgical group (p < 0.001).

TIDN surgery combined with hematoma drainage may serve as a viable surgical alternative for basal ganglia hemorrhage patients. This approach appears to reduce mannitol usage, mitigate craniotomy-associated risks, and promote short-term improvements in GCS scores and Barthel Index, highlighting its potential clinical benefits.

Figures